Samsung Active Asset Management today launched the KoAct US Biohealthcare Active ETF on the Korea Exchange (KRX). This thematic product aims to capture growth opportunities in the US biotechnology and healthcare sector.
Sign up to our free newsletters
Samsung Active Asset Management
Thematic ETF on US healthcare debuts in Korea
The fund, which uses the Solactive US Biohealthcare Index PR as its benchmark, focuses on US companies in the biotechnology and healthcare sectors, selecting 90 companies to offer diversified exposure to this transforming market.
The Product and its Strategy
Technical Characteristics of the ETF
| Parameter | Detail |
|---|---|
| Name | KoAct US Biohealthcare Active ETF |
| Code | 0113G0 KS |
| ISIN | KR70113G0000 |
| Benchmark | Solactive US Biohealthcare Index PR |
| Total Expense Ratio | 0.5% |
| Listing Date | November 11, 2025 |
| Issuer | Samsung Active Asset Management |
The Solactive US Biohealthcare Index, to which the fund refers, applies a market capitalization-weighted methodology, which includes a 10% cap for the top three companies and a 3% cap for all others. This approach aims to balance exposure between established leaders and emerging innovators.
The Sector Context and Samsung’s Strategy
The launch is part of a broader strategy by Samsung Active Asset Management, which through the KoAct brand has recently expanded its offering of sectoral thematic ETFs. Examples include the KoAct US Brain Treatment Active ETF, focused on central nervous system therapies and launched last September, and the KoAct US Natural Gas Infrastructure Active ETF, which debuted in December 2024.
The Therapeutic Innovation Pipeline
The US biohealthcare sector is undergoing a profound transformation, driven by advances in areas such as:
Precision medicine and gene editing
mRNA platforms
Integration of artificial intelligence in drug discovery and development
This innovative landscape, supported by regulatory initiatives from the US FDA, is accelerating approval times and strengthening the United States’ global leadership in medical advancement.
Timo Pfeiffer, Chief Markets Officer of Solactive, commented: “The Solactive US Biohealthcare Index captures the structural and technological tailwinds that are transforming the healthcare sector. By combining exposure to established leaders and emerging innovators, the index offers a comprehensive representation of US biohealthcare – a sector that remains at the forefront of global medical progress.”
Samsung Active Asset Management stated: “We are pleased to announce our collaboration with Solactive, with an actively managed ETF that targets leading biohealthcare companies listed in the United States. Recognizing the crucial importance of the biohealthcare sector in shaping the future of global innovation, this ETF provides investors with direct exposure to pioneering companies at the forefront of medical advances. At Samsung Active Asset Management, we are committed to providing products that enable investors to seamlessly participate in transformative global market opportunities.”
Future Prospects
The KoAct US Biohealthcare Active ETF offers Korean and international investors a specialized vehicle to access a rapidly evolving sector, whose fundamental drivers – including an aging population and the growing prevalence of chronic diseases – suggest long-term growth potential. With this launch, Samsung Active Asset Management further consolidates its presence in the sectoral thematic ETF segment, particularly within healthcare.
Source : ETFWorld.co.uk
Subscribe to Our Newsletter
